Future of IIM Treatment
Preview
Open in TheBrain
IIM Treatment Perspectives
Articles
Parents
IIM Treatment Perspectives
Children
19 Long-Term Treatment With Azathioprine and Mycophenolate Mofetil forMyositis-Related Interstitial Lung Disease
21 Study of Tofacitinib In Refractory Dermatomyositis (STIR)
22 British Society for Rheumatology guideline onmanagement of paediatric, adolescent and adultpatients with idiopathic inflammatory myopathy
22 Ef cacy of intravenous immunoglobulins (IVIg) in improvingskin symptoms in patients with dermatomyositis
22 The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies
22 Trial of Intravenous Immune Globulinin Dermatomyositis
22. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis
23 Rituximab versus intravenous cyclophosphamide in patientswith connective tissue disease-associated interstitial lungdisease in the UK (RECITAL)
23. Analysis - Rituximab compared to intravenous cyclophosphamide inadults with connective tissue disease-associated interstitiallung disease
23. Rescue combination treatment of anti-MDA5-associated ARDS withdaratumumab
24 Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy
25 Dazukibart
25 Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous- Sub-analysis of the ProDERM Study
25 Experience on the Use of Obinutuzumab o! Label in Patients with Refractory Idiopathic In"ammatory Myopathy
25 Real-world experience of anifrolumab in 30 patients withrefractory DM
25 Treatment guidelines for idiopathic inflammatorymyopathies in adults
25. Upadacitinib therapy in refractoryinflammatory myositis
25. VALOR Positive Phase 3 Study Results for Brepocitinib
Jumps
22. Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases